MedTrace Logo

Phase I Study of Nimotuzumab in Solid Tumours

NCT00369252 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2007-02-28

No results posted yet for this study

Summary

This is a phase I trial of nimotuzumab that will be conducted in patients with advanced incurable solid tumors. This is a dose-seeking study to determine the maximum tolerated and recommended phase II doses of nimotuzumab that can be safely given to patients with advanced and/or metastatic solid tumors.

Conditions

  • Advanced and/or Metastatic Solid Tumours

Interventions

DRUG

Nimotuzumab (TheraCIM h-R3)

Sponsors & Collaborators

  • CIMYM BioSciences

    collaborator OTHER

  • YM BioSciences

    lead INDUSTRY

Principal Investigators

  • Eric Chen, MD · University Health Network, Toronto

  • Lillian Siu, MD · University Health Network, Toronto

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00369252 on ClinicalTrials.gov